MedTrace Logo

Effect of Empagliflozin on Ventricular Repolarization.

NCT04117763 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-05-08

No results posted yet for this study

Summary

The present project aims to investigate if the empagliflozin has an antiarrhythmic action. Analyzing the T-wave heterogeneity index, a new electrocardiographic risk marker associated with the prediction of cardiovascular risk, in diabetic patients and coronary artery disease, the investigators will verify if empagliflozin is associated with a reduction in electrical instability.

Conditions

Interventions

DRUG

Empagliflozin 25 MG

Empagliflozin once daily, for three months

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Bruno Caramelli, MD, PhD · University of Sao Paulo

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-04
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04117763 on ClinicalTrials.gov